secwatch.observer — SEC 8-K summary
======================================

Issuer:     IGC Pharma, Inc. (IGC)
CIK:        0001326205
Form:       8-K
Filed at:   2022-03-23T23:59:59+00:00
Accession:  0001185185-22-000312
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

IGC appoints Claudia Grimaldi to Board as non-independent director
------------------------------------------------------------------

- Claudia Grimaldi appointed to the Board as non-independent director, effective March 23, 2022.
- Board now has 5 directors, majority independent; Grimaldi currently VP, Principal Finance Officer, and CCO.
- Grimaldi's employment agreement provides $150K base salary, benefits, and 18-month severance on termination without cause.
- She also serves as Managing Director of Hamsa Biochem SAS (Colombia subsidiary) and director of India subsidiary.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1326205/000118518522000312/0001185185-22-000312-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1326205/000118518522000312/indiaglob20220323_8k.htm
  HTML page:      https://secwatch.observer/filing/0001185185-22-000312

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer